yemenjmedYemen Journal of MedicinecoVolume 3 Issue 2MultidisciplinaryEnglishMay-August 2024NNY20240911ArticleRenal denervation benefits in chronic kidney disease: An updated reviewEnglishY8196Elmukhtar M. Habas1EnglishNKhaledAlarbi1EnglishYAlaHabas2EnglishYMohamedBaghi1EnglishYEshrakHabas2EnglishYAmnnaRayani3EnglishYAbdusslamSaid4EnglishYKalifaFarfar1EnglishYAlMehdiErrayes1EnglishYGamalAlfitori1EnglishYAmlHabas3EnglishYAbdel NaserElzouki1EnglishY10.18231/j.yjom.2024.004Hypertension (HTN) may not be properly controlled despite the ideal blood pressure (BP)-lowering drugs and good patient compliance. These scenarios emphasize the need for innovative approaches to treat HTN cases that are difficult to manage pharmaceutically. Numerous recent studies have documented the effectiveness of renal denervation (RDN) therapy in reducing sympathetic nerve system (SNS) overactivity. Although this therapy is invasive and expensive, its appropriate use in specific cases is still being refined. SNS overactivity is documented in HTN, chronic kidney disease (CKD), and end-stage renal disease patients. Over the past decade, RDN therapy has been used in different countries to treat HTN, with a positive response in most cases. However, some hospitals have no resources or interventionists to perform these procedures. Nonetheless, there is an increased number of physicians expressing interest in using RDN in sustained HTN therapy and prevention of CKD progression. There are no consensus guidelines worldwide; however, some societies have developed guidelines for using RDN based on updated information covering the BP-lowering mechanism, efficacy, patient selection, post- and preprocedural assessment, and procedural safety. In this review, we aimed to evaluate the effectiveness of the RDN procedure for treating HTN and prevention of CKD development and progression.EnglishResistant HTN, BP, HTN, RDN, CKD and RDN, RDN prevent CKD progressionhttps://yemenjmed.com/admin/abstract?id=109References16191. Ram CV, Iyengar SS, Wander G, Nair T, Kumar AS, Ray S, et al. Renal denervation therapy for hypertension: truths and halftruths: Renal denervation therapy for hypertension. AsiaIntervention. 2021;7(1):62and;ndash;70.2. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al. Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020;76(2):333and;ndash;74.3. (NCD-RisC NRFC. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957and;ndash;80.4. Roubsanthisuk W, Kunanon S, Chattranukulchai P, Panchavinnin P, Wongpraparut N, Chaipromprasit J, et al. Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society. Hypertens Res. 2022;46(4):898and;ndash;912.5. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(7):1124and;ndash;64.6. Sakboonyarat B, Rangsin R, Kantiwong A, Mungthin M. Prevalence and associated factors of uncontrolled hypertension among hypertensive patients: a nation-wide survey in Thailand. BMC Res Notes. 2019;12(1):380.7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275and;ndash;81.8. Scalise F, Trevano FQ, Toscano E, Sorropago A, Vanoli J, Grassi G, et al. Renal Denervation in End-Stage Renal Disease: Current Evidence and Perspectives. High Blood Press Cardiovasc Prev. 2024;31(1):7and;ndash;13.9. Mohammad AA, Nawar K, Binks O, Abdulla MH. Effects of renal denervation on kidney function in patients with chronic kidney disease: a systematic review and meta-analysis. J Hum Hyper. 2024;38(1):29and;ndash;44.10. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertensionand;ndash;its identification and epidemiology. Nat Rev Nephrol. 2013;9(1):51and;ndash;9.11. Ghofrani H, Weaver FA, Nadim MK. Resistant hypertension: medical management and alternative therapies. Cardiol Clin. 2015;33(1):75and;ndash;87.12. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley J. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204and;ndash;18.13. Mancia G, Kreutz R, Brunstrand;ouml;m M, Burnier M, Grassi G, Januszewicz A. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874and;ndash;2071.14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):510and;ndash;36.15. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012;79(7):498and;ndash;500.16. Myat A, Redwood SR, Qureshi AC, Thackray S, Cleland JC, Bhatt DL, et al. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv. 2013;6(2):184and;ndash;97.17. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Band;ouml;hm M. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903and;ndash;12.18. Kandzari DE, Bhatt DL, Sobotka PA, Oand;#39;neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35(9):528and;ndash;63.19. Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014;63(18):1924and;ndash;9.20. Bhatt DL, Kandzari DE, Neill O, Katzen JM, Agostino D, Flack R, et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. New Engl J Med. 2014;370(15):1393and;ndash;401.21. Delland;rsquo;oro R, Trevano FQ, Seravalle G, Zanchettin F, Bertoli S, Airoldi F, et al. Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. Hypertension.2019;74(4):903and;ndash;12.22. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, et al. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016;67(2):387and;ndash;96.23. De Beus E, Van Der Sande N, Bots ML, Spiering W, Voskuil M, Visseren F. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. BMJ Open. 2017;7(9):e016692.24. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64(5):1012and;ndash;33.25. Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkossy O. Chronic Fluid Overload and Mortality in ESRD. J Am Soc Nephrol. 2017;28(8):2491and;ndash;8.26. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932and;ndash;6.27. Feihl F, Liaudet L, Levy BI, Waeber B. Hypertension and microvascular remodelling. Cardiovasc Res. 2008;78(2):274and;ndash;85.28. Kaur J, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. Int J Mol Sci. 2017;18(8):1682.29. Coutsos M, Sala-Mercado JA, Ichinose M, Li Z, Dawe EJ, Leary O, et al. Muscle metaboreflex-induced coronary vasoconstriction limits ventricular contractility during dynamic exercise in heart failure. Am J Physiol Heart Circ Physiol. 2013;304(7):1029and;ndash;66.30. Volders PG. Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm. 2010;7(12):1900and;ndash;6.31. Dibona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002;11(2):197and;ndash;200.32. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125(11):1402and;ndash;15.33. Thijssen DH, De Groot P, Kooijman M, Smits P, Hopman MT. Sympathetic nervous system contributes to the age-related impairment of flow-mediated dilation of the superficial femoral artery. Am J Physiol Heart Circ Physiol. 2006;291(6):3122and;ndash;31.34. Kaplan JR, Manuck SB. Using ethological principles to study psychosocial influences on coronary atherosclerosis in monkeys. Acta Physiol Scand Suppl. 1997;640:96and;ndash;105.35. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11(8):1469and;ndash;78.36. Strojek K, Grzeszczak W, Gand;oacute;rska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12(3):602and;ndash;7.37. Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T. Sufficient and Persistent Blood Pressure Reduction in the Final LongTerm Results From SYMPLICITY HTN-Japan - Safety and Efficacy of Renal Denervation at 3 Years. Circ J. 2019;83(3):622and;ndash;31.38. Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongpraparut N. Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium. Hypertension. 2020;75(3):590and;ndash;602.39. Kario K, Kanegae H, Tomitani N, Okawara Y, Fujiwara T, Yano Y. Nighttime Blood Pressure Measured by Home Blood Pressure Monitoring as an Independent Predictor of Cardiovascular Events in General Practice. Hypertension. 2019;73(6):1240and;ndash;1248.40. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015;66(6):1130and;ndash;7.41. Kario K. Essential manual on perfect 24-hour blood pressure management from morning to nocturnal hypertension: up-to-date for anticipation medicine. vol. 2018. Japan: Wiley Publishing;. p. 1and;ndash;309.42. Kario K. Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. Hyper Res. 2009;32(6):428and;ndash;60.43. Kimura G. Kidney and circadian blood pressure rhythm. Hypertension. 2008;51(4):827and;ndash;35.44. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Band;ouml;hm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733and;ndash;74.45. Kiuchi MG, Esler MD, Fink GD, Osborn JW, Banek CT, Band;ouml;hm M. Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(23):3006and;ndash;23.46. Grimson KS, Orgain ES, Anderson B, Angelo D. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;138(4):532and;ndash;79.47. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476and;ndash;86.48. Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Band;ouml;hm M. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC Cardiovasc Interv. 2020;13(4):471and;ndash;84.49. Bhatt DL, Kandzari DE, Neill O, Katzen JM, Aagostino D, Flack R, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393and;ndash;401.50. Panchavinnin P, Wanthong S, Roubsanthisuk W, Tresukosol D, Buranakitjaroen P, Chotruangnapa C. Long-term outcome of renal nerve denervation (RDN) for resistant hypertension. Hyper Res. 2022;45(6):962and;ndash;8.51. Chia YC, Ahmad W, Fong WA, Rosman A, Rahman A. Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension. Hypertens Res. 2022;45(7):1111and;ndash;33.52. Schmieder R, Burnier M, East C, Tsioufis K, Delaney S. Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension. Interv Cardiol. 2023;18:1and;ndash;6.53. Feyz L, Theuns DA, Bhagwandien R, Strachinaru M, Kardys I, Van Mieghem N. Atrial fibrillation reduction by renal sympathetic denervation: 12 monthsand;rsquo; results of the AFFORD study. Clin Res Cardiol. 2019;108:634and;ndash;76.54. Jiang Z, Zhou X, Chen C, Wang Y, Fang P, Geng J. Renal Denervation for Ventricular Arrhythmia in Patients with Implantable Cardioverter Defibrillators Experience in Asian Population. Int Heart J. 2018;59(2):328and;ndash;60.55. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Band;ouml;hm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901and;ndash;10.56. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23(7):1250and;ndash;7.57. Nestel P, Lyu R, Low LP, Sheu WH, Nitiyanant W, Saito I, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pacific J Clin Nut. 2007;16(2):362and;ndash;7.58. Trevano FQ, Seravalle G, Grassi G, Mancia G. Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation. Curr Hypertens Rep. 2021;23(2):1and;ndash;10.59. Seravalle G, Mancia G, Grassi G. Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease. . High Blood Pressur Cardiova Prev. 2014;21:89and;ndash;105.60. Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Tarazi FF. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912and;ndash;20.61. Grassi G, Trevano FQ, Seravalle G, Arenare F, Volpe M, Furiani S. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846and;ndash;51.62. Rubinger D, Backenroth R, Sapoznikov D. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin Dial. 2013;26(3):333and;ndash;76.63. Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol. 2010;3(5):553and;ndash; 62.64. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441and;ndash;51.65. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Zadeh KK, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622and;ndash;54.66. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study. Lancet. 2017;395(10225):709and;ndash;42.67. Kandzari DE, Townsend RR, Bakris G, Basile J, Bloch MJ, Cohen DL, et al. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021;98(3):416and;ndash;42.68. Williams B, Mancia G, Spiering W, Rosei A, Azizi E, Burnier M, et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021and;ndash;104.69. Schmieder RE. Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrol Dial Transplant. 2023;38(5):1089and;ndash;96.70. Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. Front Med (Lausanne). 2018;5:82.and;nbsp;71. Schmieder RE. Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant. 2022;37(4):638and;ndash;82.72. Mallamaci F, Tripepi G. Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts. J Clin Med. 2024;13(3):678.73. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP, et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33(6):521and;ndash;9.74. Grassi G, Seravalle G, Brambilla G, Trabattoni D, Cuspidi C, Corso R. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension. 2015;65(6):1209and;ndash;25.75. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457and;ndash;64.76. Osborn JW, Tyshynsky R, Vulchanova L. Function of Renal Nerves in Kidney Physiology and Pathophysiology. Annu Rev Physiol. 2021;83:429and;ndash;50.77. Anguiano L, Riera M, Pascual J, Valdivielso JM, Barrios C, Betriu A, et al. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. Atherosclerosis. 2016;253:135and;ndash;43.78. Hu L, Zhu DN, Yu Z, Wang JQ, Sun ZJ, Yao T. Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats. J Appl Physiol. 1985;92(5):2153and;ndash;61.79. Allen AM. Blockade of angiotensin AT1-receptors in the rostral ventrolateral medulla of spontaneously hypertensive rats reduces blood pressure and sympathetic nerve discharge. J Renin Angiotensin Aldosterone Syst. 2001;2(1):120and;ndash;4.80. Davisson RL. Physiological genomic analysis of the brain reninangiotensin system. Am J Physiol Regul Integr Comp Physiol. 2003;285(3):498and;ndash;511.81. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14(2):425and;ndash;55.82. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. New Engl J Med. 1999;340(17):1321and;ndash;9.83. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hyper. 2002;15(8):717and;ndash;41.84. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86(3):901and;ndash;41.85. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974and;ndash;83.86. Desir GV, Peixoto AJ. Renalase in hypertension and kidney disease. Nephrol Dial Transplant. 2014;29(1):22and;ndash;30.87. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275and;ndash;80.88. Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008;117(10):1277and;ndash;82.89. Mungrue I, Bredt D, Stewart D, Husain M. From molecules to mammals: whatand;rsquo;s NOS got to do with it? Acta Physiol Scandinavica. 2003;179(2):123and;ndash;58.90. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999;33(4):937and;ndash;79.91. Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(8):1809and;ndash;28.92. Harada S, Tokunaga S, Momohara M, Masaki H, Tagawa T, Imaizumi T. Inhibition of nitric oxide formation in the nucleus tractus solitarius increases renal sympathetic nerve activity in rabbits. Circ Res. 1993;72(3):511and;ndash;7.93. Hansen J, Jacobsen TN, Victor RG. Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertension. 1994;24(4):439and;ndash;83.94. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001;59(4):1466and;ndash;72.95. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2620and;ndash;7.96. Kielstein JT, Band;ouml;ger RH, Bode-Band;ouml;ger SM, Frand;ouml;lich JC, Haller H, Ritz E, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13(1):170and;ndash;6.97. Mallamaci F, Tripepi G, Maas R, Malatino L, Band;ouml;ger R, Zoccali C, et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15(2):435and;ndash;76.98. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16(8):2449and;ndash;55.99. Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1115and;ndash;35.100. Watson CP, Pazarentzos E, Fidanboylu M, Padilla B, Brown R, Thomas SA, et al. The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro. Brain Res. 2016;1648(A):232and;ndash; 74.101. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Band;ouml;ger SM, Haller H. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16(8):2456and;ndash;61.102. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4(4):33and;ndash;40.103. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, Macallister R. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23(8):1455and;ndash;64.104. Augustyniak RA, Victor RG, Morgan DA, Zhang W. L-NAME-and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integrat Comp Physiol. 2006;290(3):726and;ndash;58.105. Cantarin MM, Menezes DW, Lin Z, Falkner B. Uremia induces adipose tissue inflammation and muscle mitochondrial dysfunction. Nephrol Dialysis Transpl. 2017;32(6):943and;ndash;51.106. Takahashi N, Morimoto S, Okigaki M, Seo M, Someya K, Morita T. Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. Nephrol Dialy Transp. 2010;26(4):1252and;ndash;9.107. Hirooka Y, Kishi T, Sakai K, Takeshita A, Sunagawa K. Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am J Physiol Regul Integr Comp Physiol. 2011;300(4):818and;ndash;44.108. Nishihara M, Hirooka Y, Matsukawa R, Kishi T, Sunagawa K. Oxidative stress in the rostral ventrolateral medulla modulates excitatory and inhibitory inputs in spontaneously hypertensive rats. J Hypertens. 2012;30(1):97and;ndash;106.109. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141and;ndash;9.110. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY, et al. NADPH oxidase-derived superoxide anion mediates angiotensin IIinduced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. Circ Res. 2005;97(8):772and;ndash; 80.111. Patel KP, Mayhan WG, Bidasee KR, Zheng H. Enhanced angiotensin II-mediated central sympathoexcitation in streptozotocin-induced diabetes: role of superoxide anion. Am J Physiol Regul Integr Comp Physiol. 2011;300(2):311and;ndash;31.112. Shi Z, Chen AD, Xu Y, Chen Q, Gao XY, Wang W, et al. Longterm administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pfland;uuml;gers Archiv-Eur J Physiol. 2009;458(2):247and;ndash;57.113. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092and;ndash;7.114. Dibona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2000;279(5):1517and;ndash;41.115. Silverwatch J, Marti KE, Phan MT, Amin H, Roman YM, Pasupuleti V, et al. Renal Denervation for Uncontrolled and Resistant Hypertension: Systematic Review and Network MetaAnalysis of Randomized Trials. J Clin Med. 2021;10(4):782.116. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659and;ndash;67. 117. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002;105(15):1797and;ndash;803.118. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther. 2008;326(1):278and;ndash;85.119. Lewandowski J, Symonides B, Gaciong Z, Sinski M. The effect and;acute; of statins on sympathetic activity: a meta-analysis. Clin Auto Res. 2015;25(2):125and;ndash;56.120. Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens. 2011;29(11):2176and;ndash;80.121. Chung CM, Lin MS, Hsu JT, Hsiao JF, Chang ST, Pan KL, et al. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol. 2017;11(2):422and;ndash;53.122. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? Qjm. 2017;110(8):493and;ndash;500.123. Bruno RM, Daghini E, Ghiadoni L, Sudano I, Rugani I, Varanini M, et al. Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr. 2012;96(2):302and;ndash; 10.124. Gomes ME, Messaoudi SE, Lenders JW, Bellersen L, Verheugt FW, Smits P. High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure. J Clin Pharm Ther. 2011;36(5):546and;ndash;52.125. Tahara N, Yamagishi S, Mizoguchi M, Tahara A, Imaizumi T. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res. 2013;16(5):344and;ndash;51.126. Katholi RE, Rocha-Singh KJ. sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance? . Prog Cardiov Dis. 2009;52(3):243and;ndash;51.127. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49(2):373and;ndash;82.128. Bhatt DL, Kandzari DE, Neill O, Katzen JM, Agostino D, Flack R, et al. A controlled trial of renal denervation for resistant hypertension. New Engl J Med. 2014;370(15):1393and;ndash;401.129. Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P, Tsioufis C, et al. Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol. 2014;12(1):47and;ndash;54.130. Kiuchi MG, Maia GL, Carreira MDQ, Kiuchi T, Chen S, Andrea BR, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34(28):2114and;ndash;35.131. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with endstage renal disease. Int J Cardiol. 2013;168(3):2214and;ndash;34.132. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619and;ndash;45.133. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765and;ndash;73.134. Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, et al. Chronic kidney disease in the hypertensive patient: an overview of the I-DEMAND study. High Blood Press Cardiovasc Prev. 2011;18(1):31and;ndash;7.135. Johansen KL, Chertow GM, Gilbertson DT, Ishani A, Israni A, Ku E, et al. US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 1931;81(1):8and;ndash;11.136. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16(2):529and;ndash;38.137. Sarafidis PA, Persu A, Agarwal R, Burnier M, De Leeuw P, Ferro CJ, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertensionand;nbsp;(ESH). Nephrol Dial Transplant. 2017;32(4):620and;ndash;60.138. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933and;ndash;42.139. Sata Y, Schlaich MP. The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. J Cardiovasc Pharmacol Ther. 2016;21(4):344and;ndash;52.140. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974and;ndash;83.141. Aldiabat M, Alabdallah K, Kofahi A, Aziz S. Bilateral Nephrectomy, the Forgotten Measure in the Treatment of Refractory Hypertension in Patients With End-Stage Renal Disease: A Case Report and Literature Review. Cureus. 2020;12(7):9031.142. Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hyper (Greenwich). 2012;14(11):799and;ndash;801.143. Scalise F, Sole A, Singh G, Sorropago A, Sorropago G, Ballabeni C, et al. Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. J Hypertens. 2020;38(5):936and;ndash;78.144. Xia M, Liu T, Chen D, Huang Y. Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease: a meta-analysis. Int J Hyperthermia. 2021;38(1):732and;ndash;74.145. Bruno RM, Taddei S, Borghi C, Colivicchi F, Desideri G, Grassi G. Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficultto-Treat Hypertensive Patient. High Blood Press Cardiovasc Prev. 2020;27(2):109and;ndash;26.146. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, singleblind, randomised, sham-controlled trial. Lancet. 2018;391:2335and;ndash;80.147. Band;ouml;hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444and;ndash;51.148. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Singh KR, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400:1405and;ndash; 21.149. Biffi A, Dell R, Trevano FQ, Cuspidi C, Corrao G, Mancia G, et al. Effects of Renal Denervation on Sympathetic Nerve Traffic and Correlates in Drug-Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2023;80(3):659and;ndash;67.150. Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, et al. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention. 2022;18(8):677and;ndash;85.151. Esler MD, Band;ouml;hm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752and;ndash;61.152. Kiuchi MG, Graciano ML, Carreira MA, Kiuchi T, Chen S, Lugon JR, et al. Long-Term Effects of Renal Sympathetic Denervation on Hypertensive Patients With Mild to Moderate Chronic Kidney Disease. J Clin Hyper (Greenwich). 2016;18(3):190and;ndash;6.153. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119and;ndash;48.154. Prasad B, Berry W, Goyal K, Dehghani P, Townsend RR. Central Blood Pressure and Pulse Wave Velocity Changes Post Renal Denervation in Patients With Stages 3 and 4 Chronic Kidney Disease: The Regina RDN Study. Can J Kidney Health Dis. 2019;6:2054358119828388. doi:10.1177/2054358119828388.